Agendia to Present New Data at SABCS 2019 Demonstrating How Comprehensive Genomic Profiling Benefits Early-Stage Breast Cancer Patients
PRESS RELEASE Data evaluating MammaPrint® and BluePrint® includes new risk Read More
PRESS RELEASE Data evaluating MammaPrint® and BluePrint® includes new risk Read More
PRESS RELEASE IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – Read More
PRESS RELEASE IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – Read More
PRESS RELEASE New data presented at ASCO underscores importance of Read More
PRESS RELEASE IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – 31 Read More
PRESS RELEASE IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – 21 Read More
PRESS RELEASE ER+ breast cancer patients reclassified as ER+ Read More
PRESS RELEASE Simultaneous creation of Global Lab Center of Excellence Read More
PRESS RELEASE Determination finds that Agendia’s MammaPrint® Breast Cancer Risk Read More
PRESS RELEASE New Studies Show MammaPrint® and BluePrint® Tests Provide Read More